ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Ribociclib/Endocrine Therapy & Improved PFS with Capivasertib + Fulvestrant

461 views
September 12, 2019
0 Comments
Login to view comments. Click here to Login